How do colchicine and anti-interleukin-1 agents compare in efficacy and safety for reducing the risk of recurrent pericarditis?
Both colchicine and anti-interleukin-1 agents effectively reduce recurrent pericarditis, but anti-interleukin-1 agents have a higher rate of nonserious adverse events.
Both colchicine and anti-interleukin-1 agents are effective in reducing the risk of recurrent pericarditis. Anti-interleukin-1 agents are associated with more frequent nonserious adverse events, but evidence on serious adverse events remains inconclusive.
Ehsan et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: